EXAS
Exact Sciences CorporationHealthcare · $20.0B market cap
Verdict
We can't put a fair value on EXAS right now. It has lost money in each of its last 3 years, and our valuation needs recent profits to project from.
Business quality
3 of 5 clear the 10% bar. What are the Big Five?
Follow EXAS
Track it on your watchlist and see the full analysis. Free.
Create a free accountSuperinvestors
None of the investors we track holds EXAS right now. In Q1 2026, 1 sold out. Who we track
Moves in Q1 2026
Sold out: Mairs & Power Funds
About Exact Sciences Corporation
Exact Sciences Corporation specializes in developing and distributing cancer screening and diagnostic tools across the United States and internationally. Their key product, Cologuard, is an innovative, non-invasive test that analyzes stool-based DNA to identify specific DNA and hemoglobin biomarkers indicative of colorectal cancer and precancerous conditions. The company's extensive portfolio also includes the…
Medical - Diagnostics & Research
Fair value and Payback Price are estimates from the company's reported financials, not investment advice. Prices as of the close of Mar 23, 2026. How the Payback Price works